Abstract:Because little is known about the interactions between herbal products and standard medications, the effects of seven ginsenosides and two eleutherosides (active components of the ginseng root) on the catalytic activity of c-DNA expressed cytochrome P450 isoforms were studied in in vitro experiments. Increasing concentrations of ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, and Rg1 and eleutherosides B and E were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format. For each test substance, the IC50 (the concentration required to inhibit the metabolism of the surrogate substrates by 50%) was estimated and this value compared with that obtained for positive control inhibitory drugs furafylline, sulfaphenazole, tryanylcypromine, quinidine, and ketoconizole. Of the components tested, three ginsenosides (Rd, Rc, and Rf) modified the activity of the recombinant enzymes. Ginsenoside Rd produced weak inhibitory activity against the surrogate substrates for CYP3A4 and CYP2D6 and even weaker inhibitory activity against the surrogate substrates for CYP2C19 and CYP2C9. The IC50 values of 58 and 74 uM for the two substrates for CYP3A4 are orders of magnitude higher than that for the potent inhibitor ketoconazole used as a positive control. Ginsenoside Rc produced an increase in the activity of CYP2C9 (70% at 200 uM) and ginsenoside Rf produced an increase in the activity of CYP3A4 (54% at 200 uM). The biological significance of this is unclear at this time. Enzyme "activation", the process by which direct addition of one compound to an enzyme enhances the rate of reaction of the substrate, has been observed in a number of cases with P450 enzymes; however, a matrix effect caused by the test compound fluorescing at the same wavelength as the metabolite of the marker substrate cannot be ruled out. In summary, these studies suggest that the ginsenosides and eleutherosides tested are not likely to inhibit the metabolism of coadministered medications in which the primary route of elimination is via cytochrome P450; the potential of ginsenosides to enhance the catalysis of certain substrates requires further investigation.

Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides.

Structure-activity Relationship and Substrate-Dependent Phenomena in Effects of Ginsenosides on Activities of Drug-Metabolizing P450 Enzymes.

Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes

Ginsenoside Metabolites Inhibit P-Glycoprotein in Vitro and in Situ Using Three Absorption Models

The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity.

Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs).

Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity

Suppression Of Hepatic Cyp1a2 By Total Ginsenosides In Lipopolysaccharide-Treated Mice And Primary Mouse Hepatocytes

Influence of Ginsenoside Rh-1 and F-1 on Human Cytochrome P450 Enzymes

Molecular Mechanisms Governing Different Pharmacokinetics of Ginsenosides and Potential for Ginsenoside-Perpetrated Herb-Drug Interactions on Oatp1b3

Pharmacokinetic Studies of Chemical Constituents of Ginseng

Inhibitory Effects of Herbal Constituents on P-glycoprotein in Vitro and in Vivo: Herb-Drug Interactions Mediated Via P-gp.

Lability of Traditional Chinese Medicine by Intestinal Bacterial Metabolism Results in P450 Cycle-mediated Drug-Drug Interaction

Ginseng Disrupts the Metabolism of Cerebrovascular Treatment Drug Clopidogrel

In Vitro Investigations into the Potential Drug Interactions of Pseudoginsenoside DQ Mediated by Cytochrome P450 and Human Drug Transporters

20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro And In Vivo: A Case For Herb-Drug Interactions

EFFECTS OF INDIVIDUAL GINSENOSIDES, GINKGOLIDES AND FLAVONOIDS ON CYP2C19 AND CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES

Pharmacokinetic compatibility of ginsenosides and Schisandra Lignans in Shengmai-san: from the perspective of p-glycoprotein

Qualitatively and quantitatively investigating the metabolism of 20(S)-protopanaxadiol-type ginsenosides by gut microbiota of different species

Different absorption and metabolism of ginsenosides after the administration of total ginsenosides and decoction of<i>Panax ginseng</i>

Metabolism of Ginseng and Its Interactions with Drugs.